@Article{biocell.2020.011642,
AUTHOR = {JUN ZHANG, YEHONG HUANG, WENZHUO LIU, LULU LI, LIMING CHEN},
TITLE = {Chaperone-mediated autophagy targeting chimeras (CMATAC) for the degradation of ERα in breast cancer},
JOURNAL = {BIOCELL},
VOLUME = {44},
YEAR = {2020},
NUMBER = {4},
PAGES = {591--595},
URL = {http://www.techscience.com/biocell/v44n4/40997},
ISSN = {1667-5746},
ABSTRACT = {Estrogen receptor alpha (ERα/ESR1) is overexpressed in over half of all breast cancers and is considered a
valuable therapeutic target in ERα positive breast cancer. Here, we designed a membrane-permeant Chaperonemediated Autophagy Targeting Chimeras (CMATAC) peptide to knockdown endogenous ERα protein through
chaperone-mediated autophagy. The peptide contains a cell membrane-penetrating peptide (TAT) that allows the
peptide to by-pass the plasma membrane, an αI peptide as a protein-binding peptide (PBD) that binds specifically to
ERα, and CMA-targeting peptide (CTM) that targeting chaperone-mediated autophagy. We validated that ERα
targeting peptide was able to target and degrade ERα to reduce the viability of ERα positive breast cancer cells. Taken
together, our studies provided a new method to reduce the level of intracellular ERα protein via CMATAC, and thus
may provide a new strategy for the treatment of ERα positive breast cancer.},
DOI = {10.32604/biocell.2020.011642}
}